The National Foundation for Cancer Research (NFCR), AIM-HI, and GoMo Health are collaborating to make it easier for people worldwide to discover and qualify for clinical trials that could be very helpful to them or a loved one who has cancer.
The goal of the SPARTA study is to learn if an investigational drug, called APL-101, can help patients with non-small cell lung cancer (NSCLC) or other advanced solid tumors with a genetic alteration in c-Met oncogene (such as amplification, fusion, or EXON 14 skipping mutation). Other advanced solid tumors include, but are not limited to, brain, head and neck, gastric, esophageal, biliary, pancreatic, or colorectal cancer.
Yiviva has launched a research study to investigate whether adding YIV-906 (the study drug), comprised of four naturally derived ingredients (licorice, skullcap, peony, and dates) to sorafenib (a currently available, typical treatment for liver cancer) can increase the length of time patients with hepatocellular carcinoma (HCC) live with their disease before it worsens. The evidence-based study drug is developed from an 1800-year-old Chinese formula.
Includes the development of custom marketing campaigns integrating paid media, organic social promotion, and traditional marketing.
Trial website development, patient education videos and resource guides.
Development of trial prescreener based on protocol inclusion and exclusion criteria to assess potential participant viability.
Direction of potentially qualified candidates to a referral coordinator to facilitate completion of pre-screener, and based on results, refer potential participant to nearest investigator site
Support Research for Cancer
Everyday, our scientists make progress on the fight against cancer – but we still have a long way to go on the road to a cure, and every donation helps. Your generosity today will drive breakthroughs tomorrow!